Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer

Clinical Lung Cancer

Volumn 10, Issue 4, 2009, Pages 223-229

  Hirsh, Vera ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Bisphosphonates; Bone markers; Metastases; N telopeptide; NTX; Skeletal related events; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CLODRONIC ACID; DENOSUMAB; DOXORUBICIN; GEMCITABINE; IBANDRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; INDEPENDENCE; JAW OSTEONECROSIS; KIDNEY FUNCTION; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MORBIDITY; NONHUMAN; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; SPINAL CORD COMPRESSION;

EID: 70349446638     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.030     Document Type: Review

References (61)

1. Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med 2004; 25 (suppl 1):3-10.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58 : 71-96.
3. Laskin JJ, Sandler AB. First-line treatment for advanced non-small-cell lung cancer. Oncology (Williston Park) 2005; 19 : 1671-1676; discussion 1678-80.
4. Hong WK, Tsao AS. Lung carcinoma. In: Porter RS, Kaplan JL, Homeier BP, et al. The Merck Manual Online. Updated March 2008. Available at: http://www.merck.com/mmpe/[rint/sec2005/ch2062/ch2062b.html. Accessed: March 4, 2009.
5. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9 (suppl 4):14-27.
6. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9 : 509-524.
7. Iordanidou L, Trivizaki E, Saranti S, et al. Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. J BUON 2006; 11 : 491-497.
8. Schirrmeister H, Arslandemir C, Glatting G, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31 : 964-968.
9. Nackaerts KL, Langer CJ, Harper PG, et al. International consensus panel recommendations for the diagnosis of bone metastases from lung cancer. Presented at: 1st European Lung Cancer Conference; European Society for Medical Oncology- International Association for the Study of Lung Cancer; April 23-26, 2008; Geneva, Switzerland. Abstract 199PD.
10. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, doubleblind, placebo-controlled trial. Cancer 2004; 100 : 2613-2621.
11. Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57 : 229-232.
12. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67 : 390-396.
13. Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006; 1 : 571-576.
14. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16 : 579-584.
15. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007; 110 : 1860-1867.
16. Saba N, Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part I: Mechanisms of action, role of biomarkers and preclinical applications. Oncology 2005; 68 : 10-17. (Pubitemid 40675003)
17. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006; 14 : 408-418.
18. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19 : 420-432.
19. Caristi N, Russi EG, Adamo V, et al. [Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study]. G Ital Oncol 1990; 10 : 129-132.
20. Piga A, Bracci R, Ferretti B, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998; 17 : 213-217.
21. Saba N, Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses. Oncology 2005; 68 : 18-22. (Pubitemid 40675004)
22. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004; 2 : 205-213 discussion follows.
23. Theriault RL. Zoledronic acid (Zometa®) use in bone disease. Expert Rev Anticancer Ther 2003; 3 : 157-166.
24. Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004; 6 : 170-174.
25. Harper P, Hirsh V, Cook R. Skeletal morbidity and zoledronic acid benefits in patients with bone metastases from non-small cell lung cancer. Presented at: 12th World Conference on Lung Cancer; September 2-6, 2007; Seoul, Korea. Abstract PD6-3-8.
26. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small cell lung cancer (NSCLC) and bone metastases. Bone 2004; 34 (suppl 1):S89 (Abstract 73).
27. Longo F, Del Signore E, De Sanctis R, et al. Zoledronic acid and treatment of bone metastases in patients with advanced lung cancer (NSLCC and SCLC). Ann Oncol 2008; 19 (suppl 8):vii258 (Abstract 838).
28. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 2008; 11 : 325-338.
29. Gralow JR, Lipton A, Fizazi K, et al. Effects of denosumab on bone resorption in patients with solid tumors and bone metastases: comparison of serum-C telopeptide levels from two randomized, active-controlled, phase II trials. J Clin Oncol 2008; 26 (15 suppl):520S (Abstract 9574).
30. ClinicalTrials.gov. Phase II study of dasatinib in previously treated patients with advanced NSCLC (TOP0801). Available at: http://clinicaltrials.gov/ ct2/show/NCT00787267. Accessed February 13, 2009.
31. Maxwell C, Swift R, Goode M, et al. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurs 2003; 7 : 403-408.
32. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96 : 879-882. (Pubitemid 38807610)
33. Zometa®. [package insert]. Zoledronic acid injection prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
34. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23 : 826-836.
35. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2008; 20 : 117-120.
36. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology (Am Soc Hematol Educ Program) 2006; 356-360, 515.
37. Weitzman R, Sauter N, Eriksen EF, et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007; 62 : 148-152.
38. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008; 13 : 187-195.
39. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97 : 59-69.
40. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23 : 4925-4935.
41. Pectasides D, Nikolaou M, Farmakis D, et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 2005; 25 : 1457-1463.
42. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113 : 193-201.
43. Matczak E, Hirsh V, Lipton A, et al. Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: stratified by baseline bone alkaline phosphatase (BALP). J Clin Oncol 2006; 24 (18 suppl):421s (Abstract 7228).
44. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3 : 228-236.
45. Lu S, Zhang J, Zhou Z, et al. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 2008; 20 : 581-587.
46. Ozturk OH, Bozcuk H, Burgucu D, et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 2007; 31 : 1069-1071.
47. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34 : 453-475.
48. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18 : 482-492.
49. Coxon JP, Oades GM, Kirby RS, et al. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94 : 164-170.
50. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10 : 4559-4567.
51. Green JR. Bisphosphonates: preclinical review. Oncologist 2004; 9 (suppl 4):3-13.
52. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 2008; 34 : 183-192.
53. Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22 : 195-201.
54. Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24 : 227-230.
55. Zaghloul MS, Boutrus R, El-Hosieny H, et al. A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients [oral presentation]. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology; May 30-June 3 2008; Chicago, IL (Abstract 5033).
56. Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Breast Cancer Res Treat 2007; 106 (suppl 1):S40 (Abstract 511).
57. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360 : 679-691.
58. Frassoldati A, Brufsky A, Bundred N, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24-month integrated follow-up of the Z-FAST and ZO-FAST trials. Presented at: 33rd Congress of the European Society for Medical Oncology; September 12-16, 2008; Stockholm, Sweden. Abstract 185PD.
59. Coleman R, Thorpe H, Cameron D, et al. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04). Breast Cancer Res Treat 2006; 100 (suppl 1):S107 (Abstract 2080).
60. Winter MC, Thorpe H, Burkinshaw R, et al. Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer. Cancer Treat Rev 2008; 34(suppl):S43-S86.
61. Cook RJ, Hirsh V, Major PP, et al. Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): survival in patients with high bone turnover. J Clin Oncol 2008; 26(15 suppl):729s (Abstract 20562).